ascopubs.org

The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...
News Medical

Mutation profiles and clinicopathological correlations in lung squamous cell carcinoma

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...
Morningstar

SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of ...

Initial safety & efficacy in patients with Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations will be presented ...
Targeted Oncology

Navigating Complexity: Key Updates to ASCO's Living Guidelines for Stage IV Driver Mutation–Negative NSCLC

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
ascopubs.org

Comprehensive Genomic Profiling of Indian Patients With Lung Cancer

Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa These findings ...
MarketWatch

FDA approves HERNEXEOS(R), the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

The MarketWatch News Department was not involved in the creation of this content. This press release is not intended for UK media -- HERNEXEOS(R) (zongertinib tablets) approved based on an objective ...
Business Insider

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

HERNEXEOS ® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial 1 Accelerated approval follows Breakthrough Therapy ...